Global Dengue Pipeline Landscape Report 2024: Therapeutic Assessment and Drug Analysis of 20+ Drugs [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
The detailed analysis highlights over 20 companies and features more than 20 pipeline drugs that span across various stages from clinical to nonclinical product development. This pivotal report underlines the dedicated efforts of numerous industry and academic leaders as they navigate the complexities of Dengue research to bring forth potential treatments and improve patient outcomes. Innovation in Dengue Therapy Dengue continues to represent a significant global health concern, with increasing incidence rates necessitating a surge in therapeutic research. The report focuses on emerging drugs and their positions in different phases of development, including treatments that have reached the pre-registration phase. Among the leading entities, Takeda is recognized for having its dengue vaccine candidate, TAK-003, in the most advanced stage of development. With a strategic assessment of the dengue therapeutic landscape, this analysis provides a deeper understanding of the current t
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 [Yahoo! Finance]Yahoo! Finance
- Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024GlobeNewswire
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsGlobeNewswire
- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
AVIR
Earnings
- 2/28/24 - Miss
AVIR
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- 2/28/24 - Form 10-K
- AVIR's page on the SEC website